English
Back
Open Account
港股窩輪Jenny
commented on a stock · Mar 26 14:02

Akeso Inc. (09926) Short-term Analysis: Strong Breakthrough of Resistance, Biopharmaceutical Sector Drives Upside Momentum

As of March 26, 2026, Akeso Inc. (09926) was trading at HKD 124.6, up 1.56%, with a turnover of HKD 1.338 billion, indicating active market trading. In early trading, the share price reached a high of HKD 129.7, gaining over 4%, showcasing strong upward momentum. In the same sector, biopharmaceutical stocks generally performed well today, with Ascletis Pharma-B (01672) $ASCLETIS-B (01672.HK)$ Surging over 10.53% to HKD 15.97, while Catalent (06821) $ASYMCHEM (06821.HK)$ Followed the uptrend, reflecting a significant strengthening in sector sentiment.
From a technical perspective, after rebounding from its lows, the stock has successfully broken through multiple moving average resistances. The short-term moving average MA10 is at HKD 117.69 and has stabilized significantly, while MA30 and MA60 are located at HKD 109.76 and HKD 112.04 respectively, presenting a bullish alignment with moving averages diverging upwards, indicating that the medium-term trend has strengthened. Based on multiple technical indicators, the system's signal is 'Sell' with an intensity of 10; however, several oscillators such as the Stochastic Oscillator and CCI indicators show overbought conditions, and the Williams %R indicator issues an 'Overbought Condition, Sell Signal,' suggesting that the recent rise in stock price has been rapid, entering overbought territory with potential consolidation pressure in the short term. Nevertheless, the Bull/Bear Power Indicator, Ichimoku Cloud, and MACD signals all indicate 'Buy,' and Bollinger Bands also suggest 'Buy,' confirming that the uptrend continues. According to technical analysis data, short-term support levels are at HKD 114.6 and HKD 105.9, while resistance levels are at HKD 133.1 and HKD 144.1. The probability of an upward movement is 51%, and the 5-day volatility is 15.9%, indicating higher stock price volatility.
In terms of market news, as of March 26, Hong Kong-listed biopharmaceutical stocks collectively surged, becoming the market focus. According to Cailian Press and First Financial Daily, Ascletis Pharma rose more than 7%, Lepu Biotech and XtalPi Holdings climbed over 6%, and Akeso also increased by more than 5%, leading the sector. At today’s Hong Kong stock opening, innovative drug concept stocks performed actively, with Lepu Biotech rising over 6%, followed by Akeso moving higher. Fundamentally, Akeso will disclose its fiscal year 2025 annual report today, and the market expects sales growth of core products Cadonilimab and Eftilagimod after their inclusion in the national medical insurance system will drive performance. Bocom International, SPDB International, and other investment banks recently gave a 'buy' rating, with target prices ranging from HKD 174 to HKD 183. Moreover, the group's global leadership position in the immuno-oncology field continues to strengthen, with Eftilagimod's global multicenter clinical trials proceeding smoothly, providing momentum for medium- to long-term growth.
As of March 26, 2026, Akeso Inc. (09926) was trading at HKD 124.6, up 1.56%, with a turnover of HKD 1.338 billion, indicating active market trading. In early trading, the share price reached a high of HKD 129.7, gaining over 4%, showcasing strong upward momentum. In the same sector, biopharmaceutical stocks generally performed well today, with Ascletis Pharma-B (01672) $ASCLETIS-B (01672.HK)$ Surging over 10.53% to HKD 15.97, while Catalent (06821) $ASYMCHEM (06821.HK)$ Followed the uptrend, reflecting a significant strengthening in sector sentiment. From a technical perspective, after rebounding from its lows, the stock has successfully broken through multiple moving average resistances. The short-term moving average MA10 is at HKD 117.69 and has stabilized significantly, while MA30 and MA60 are located at HKD 109.76 and HKD 112.04 respectively, presenting a bullish alignment with moving averages diverging upwards, indicating that the medium-term trend has strengthened. Based on multiple technical indicators, the system's signal is 'Sell' with an intensity of 10; however, several oscillators such as the Stochastic Oscillator and CCI indicators show overbought conditions, and the Williams %R indicator issues an 'Overbought Condition, Sell Signal,' suggesting that the recent rise in stock price has been rapid, entering overbought territory with potential consolidation pressure in the short term. Nevertheless, the Bull/Bear Power Indicator, Ichimoku Cloud, and MACD signals all indicate 'Buy,' and Bollinger Bands also suggest 'Buy,' confirming that the uptrend continues. According to technical analysis data, short-term support levels are at HKD 114.6 and HKD 105.9, while resistance levels are at HKD 133.1 and HKD 144.1. The probability of an upward movement is 51%, and the 5-day volatility is 15.9%, indicating higher stock price volatility.
Reviewing the warrant market performance, according to the product review on March 23, the four products mentioned that day recorded significant increases in the following two days (as of March 25), successfully capturing the rebound of the underlying stocks. Among them, Societe Generale bull certificate (61054) and UBS Group bull certificate each rose by 30%, performing the most prominently; Bank of China call warrant (25994) gained 29%, and Societe Generale call warrant (25883) rose by 28%. The underlying stock rose by 8.65% during the same period, and the related bull certificates and call warrants fully demonstrated the leverage effect, showing that appropriate derivatives can effectively amplify returns in a clear rebound trend.
As of March 26, 2026, Akeso Inc. (09926) was trading at HKD 124.6, up 1.56%, with a turnover of HKD 1.338 billion, indicating active market trading. In early trading, the share price reached a high of HKD 129.7, gaining over 4%, showcasing strong upward momentum. In the same sector, biopharmaceutical stocks generally performed well today, with Ascletis Pharma-B (01672) $ASCLETIS-B (01672.HK)$ Surging over 10.53% to HKD 15.97, while Catalent (06821) $ASYMCHEM (06821.HK)$ Followed the uptrend, reflecting a significant strengthening in sector sentiment. From a technical perspective, after rebounding from its lows, the stock has successfully broken through multiple moving average resistances. The short-term moving average MA10 is at HKD 117.69 and has stabilized significantly, while MA30 and MA60 are located at HKD 109.76 and HKD 112.04 respectively, presenting a bullish alignment with moving averages diverging upwards, indicating that the medium-term trend has strengthened. Based on multiple technical indicators, the system's signal is 'Sell' with an intensity of 10; however, several oscillators such as the Stochastic Oscillator and CCI indicators show overbought conditions, and the Williams %R indicator issues an 'Overbought Condition, Sell Signal,' suggesting that the recent rise in stock price has been rapid, entering overbought territory with potential consolidation pressure in the short term. Nevertheless, the Bull/Bear Power Indicator, Ichimoku Cloud, and MACD signals all indicate 'Buy,' and Bollinger Bands also suggest 'Buy,' confirming that the uptrend continues. According to technical analysis data, short-term support levels are at HKD 114.6 and HKD 105.9, while resistance levels are at HKD 133.1 and HKD 144.1. The probability of an upward movement is 51%, and the 5-day volatility is 15.9%, indicating higher stock price volatility.
Based on technical analysis, market environment, and sector trends, Akeso is in the continuation phase after a strong breakout in the short term. Investors should consider 114.6 yuan as the short-term support level and watch the challenge at resistance levels of 133.1 yuan and 144.1 yuan. As the RSI and multiple oscillation indicators have entered the overbought zone, chasing highs in the short term requires attention to the risk of pullbacks, but the upward trend still has room to continue due to the bullish alignment of moving averages and supporting trading volumes. Below are analyses of several warrant and bull/bear certificate products with clear terms, whose recovery prices and exercise prices closely relate to technical support and resistance levels:
For bullish strategies, consider the Bank of China call warrant (25994) $BIAKESO@EC2608A.C (25994.HK)$ and Societe Generale call warrant (25883) $SGAKESO@EC2608A.C (25883.HK)$ . Both have an exercise price of 131.36 yuan, slightly below the first resistance level of 133.1 yuan, constituting a slightly out-of-the-money structure. The advantage of the Bank of China call warrant (25994) lies in its relatively lower premium, with a leverage of 3.1 times; the Societe Generale call warrant (25883) stands out with the lowest premium and implied volatility, with a leverage of 3.3 times. Both have exercise prices close to the 133.1 yuan resistance zone, suitable for investors expecting the stock price to break through this resistance and move further upwards. For those wishing to deploy closer to the support level, they can look at bull certificates with farther recovery prices, but given the substantial rise already accumulated in the underlying stock, the recovery risk of close-price bull certificates needs careful evaluation.
For bearish strategies, consider UBS Group bear certificate (64129) $UB#AKESORP2812A.P (64129.HK)$ and Societe Generale bear certificate (55049) $SG#AKESORP2812A.P (55049.HK)$ , with recovery prices of 133.45 yuan and 134.5 yuan respectively, slightly above the first resistance level of 133.1 yuan, representing an aggressive deployment near the resistance zone. The advantage of UBS Group bear certificate (64129) is its high actual leverage (7.4 times) and low premium; the Societe Generale bear certificate (55049) stands out with the highest actual leverage (7 times) and the lowest premium, suitable for investors expecting the stock price to meet resistance between 133 yuan and 134 yuan and retreat. Given the stock's current strength, bear certificate deployments require strict risk control, with attention to stop-loss arrangements after breaking through resistance.
As of March 26, 2026, Akeso Inc. (09926) was trading at HKD 124.6, up 1.56%, with a turnover of HKD 1.338 billion, indicating active market trading. In early trading, the share price reached a high of HKD 129.7, gaining over 4%, showcasing strong upward momentum. In the same sector, biopharmaceutical stocks generally performed well today, with Ascletis Pharma-B (01672) $ASCLETIS-B (01672.HK)$ Surging over 10.53% to HKD 15.97, while Catalent (06821) $ASYMCHEM (06821.HK)$ Followed the uptrend, reflecting a significant strengthening in sector sentiment. From a technical perspective, after rebounding from its lows, the stock has successfully broken through multiple moving average resistances. The short-term moving average MA10 is at HKD 117.69 and has stabilized significantly, while MA30 and MA60 are located at HKD 109.76 and HKD 112.04 respectively, presenting a bullish alignment with moving averages diverging upwards, indicating that the medium-term trend has strengthened. Based on multiple technical indicators, the system's signal is 'Sell' with an intensity of 10; however, several oscillators such as the Stochastic Oscillator and CCI indicators show overbought conditions, and the Williams %R indicator issues an 'Overbought Condition, Sell Signal,' suggesting that the recent rise in stock price has been rapid, entering overbought territory with potential consolidation pressure in the short term. Nevertheless, the Bull/Bear Power Indicator, Ichimoku Cloud, and MACD signals all indicate 'Buy,' and Bollinger Bands also suggest 'Buy,' confirming that the uptrend continues. According to technical analysis data, short-term support levels are at HKD 114.6 and HKD 105.9, while resistance levels are at HKD 133.1 and HKD 144.1. The probability of an upward movement is 51%, and the 5-day volatility is 15.9%, indicating higher stock price volatility.
Overall, Akeso is in the continuation phase after a strong breakout in the short term. Investors should use 114.6 yuan as the short-term bullish-bearish dividing line; if the stock price can stabilize above this support, it may further challenge the resistances at 133.1 yuan and 144.1 yuan; otherwise, attention should be paid to the 105.9 yuan support. When selecting derivative products, one should balance leverage with the distance to recovery/exercise prices based on their judgment of future market direction and intensity, while paying attention to the market's subsequent reaction after today's annual report disclosure.
$Hang Seng Index (800000.HK)$$Hang Seng TECH Index (800700.HK)$$Hang Seng China Enterprises Index (800100.HK)$Interactive Questions
Do you think Akeso Inc. (09926) can break through the resistance level of HKD 133.1 in the short term?
A. Yes, the sentiment in the pharmaceutical sector is positive, and the annual report is expected to catalyze an upward trend.
B. No, technical overbought conditions require consolidation first.
Friendly reminder: This article does not constitute any investment advice. It is for reference only and does not constitute any form of investment recommendation. The market data, opinions, and analysis contained herein may change at any time without prior notice. We assume no responsibility for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive evaluation of asset performance should be conducted using additional data. Trading decisions should not be made solely based on this article. Please note that past performance is not indicative of future results. Follow Jenny's Warrants HKEX column for more professional insights.
#Kangfang Biotech #09926 #Technical Analysis #Support Level #Resistance Level #Warrants #Bull and Bear Certificates #Call Warrants #Biopharmaceuticals #Hong Kong Stock Warrants Jenny
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
1
364K Views
Report
Comments
Write a Comment...
1
13